Trial Profile
Phase IIa trial of MUC-1 Dendritic Cell Vaccine [CVac] in patients with advanced ovarian cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2017
Price :
$35
*
At a glance
- Drugs Cancer vaccine MUC-1 (Primary)
- Indications Ovarian cancer
- Focus Biomarker; Therapeutic Use
- Acronyms CAN-002
- Sponsors Immutep Limited; Prima BioMed
- 28 Nov 2017 According to a Prima BioMed media release, Prima BioMed changed its name to Immutep Limited.
- 21 Feb 2011 New trial record